Indeed, our data strongly suggest that methylation zygosity should be assessed in contemporaneous tumor samples before any firm conclusions are drawn regarding the impact of BRCA1 methylation on therapeutic efficacy29,33. This evidence concerns the gene BRCA1 and neoplasm.